Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.30527 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
Haematologica
December 2023
Center for Lymphoid Cancer, Division of Medical Oncology BC Cancer and the University of British Columbia, British Columbia, Vancouver.
Peripheral T-cell lymphomas (PTCL) encompass over 30 different entities and although they share post-thymic T- or NK-cell derivation, the disease biology and genomic landscape are very diverse across subtypes. In Western populations, nodal PTCL are the most frequently encountered entities in clinical practice and although important achievements have been made in deciphering the underlying biology and in therapeutic advances, there are still large gaps in disease understanding and clinical scenarios in which controversy over best practice continues. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)- based chemotherapy continues to be the 'standard' treatment, with the addition of brentuximab vedotin (BV) in the combination CHP (cyclosphosphamide, doxorubicin, prednisone)-BV representing a new treatment paradigm in CD30+ PTCL although its benefit is less certain in the non-anaplastic large cell lymphoma subtypes.
View Article and Find Full Text PDFComment on: Brentuximab vedotin-related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity?
Pediatr Blood Cancer
November 2023
Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge - Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!